Avalyn Pharma Inc.

US$29.15As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:AVLNHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE —
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap US$1.292B
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$35
20.17%
(68.14%)
Hold 1|12|4|4|7
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.52
0.50
0.53
0.58
43.62%
25.01%
20.15%
21.95%
Revenue$M
136.5
137.7
134.6
131.5
0.40%
(1.41%)
(3.44%)
(5.32%)
Peers (US$1.292B)
Cap (US$)
PE
1.280B
130.9x
Capital
TTM
5Y
10Y
Leveragex
0.561
0.128
0.117
EBIT/Intx
1.035
0.109
0.109
Own earn%
121.61
(14.74)
(8.75)
Sh yield%
22.20
59.52
58.99
Owners
Insiders/Inst%
8.20
79.51
Short interest%
2.39
SBC / revenue%
3.20
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
8–12
$1 testx
—
Incr. ROIC%
9